Eli Lilly and Company (LLY)
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
More Records Highs for Eli Lilly Stock After Buyout
Eli Lilly And Co (NYSE:LLY) announced earlier today it will acquire Morphic Holding (NASDAQ:MORF) for $3.2 billion in cash, expanding its inflammatory bowel disease (IBD) drug portfolio.
3 No-Brainer Stocks to Buy in July
Eli Lilly could be headed for a market capitalization above $1 trillion. Regeneron has overcome bumps and shows no signs of slowing down.
Recession Alert: Play Defense While Earning Up To 10% Yield
Don't fear recessions; embrace them with a well-constructed portfolio. Market prices and business fundamentals are distinct elements. Focus on the latter. We discuss two picks from non-discretionary sectors — telecom and healthcare.
Eli Lilly Remains an Equities Outlier
New obesity and Alzheimer's disease treatments are keeping Eli Lilly and Company (LLY) at the forefront of equities excellence.
Eli Lilly Stock Price Prediction: Where Will It Be in 1 Year
24/7 Insights Wall Street expectations for where Eli Lilly and Co.
Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation
Zepbound and Mounjaro will add tens of billions in revenue to Eli Lilly's top line in the years ahead. But management is looking beyond those products and developing even more weight loss treatments.
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
On Tuesday, the FDA approved Eli Lilly and Co's LLY Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.
FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
Eli Lilly (LLY) has received Food and Drug Administration (FDA) approval for its treatment for early symptomatic Alzheimer's after studies showed that the drug was able to slow the progression of the disease.
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.
